卡培他滨,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
1352	TT	Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
1351	CT	Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
1350	CC	Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

等位基因

注释文本

Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

1351

Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

1350

Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.

id	证据的ID	总结
4094	1448994804	Allele T is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C.
4093	1448723954	Genotypes CC + CT is associated with increased likelihood of treatment interruptions when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.
4092	1448262721	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.
4091	1448124810	Genotypes CT + TT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.
4090	1448124677	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.
4089	1447945619	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.
4088	1449162055	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.
4087	827810898	Genotypes CT + TT is associated with increased likelihood of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.
4086	1450954760	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.
4085	1447987436	Genotype CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype CC.
4084	1449732030	Genotypes CT + TT are associated with increased risk of Drug Toxicity and Neutropenia when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.
4083	PA166109594	Annotation of CPIC Guideline for capecitabine and DPYD
3117	1450372243	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.
3116	1450371918	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.

证据的ID

总结

4094

1448994804

Allele T is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C.

4093

1448723954

Genotypes CC + CT is associated with increased likelihood of treatment interruptions when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.

4092

1448262721

Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.

4091

1448124810

Genotypes CT + TT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.

4090

1448124677

Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.

4089

1447945619

Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.

4088

1449162055

Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.

4087

827810898

Genotypes CT + TT is associated with increased likelihood of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.

4086

1450954760

Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.

4085

1447987436

Genotype CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype CC.

4084

1449732030

Genotypes CT + TT are associated with increased risk of Drug Toxicity and Neutropenia when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.

4083

PA166109594

Annotation of CPIC Guideline for capecitabine and DPYD

3117

1450372243

Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.

3116

1450371918

Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.

id	类型	评论
1502	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1501	Update	Added CPIC function and modified text. This changes because CPIC assigned this normal function.
1500	Update	Attached CPIC guideline and removed override.
1499	Create	Created

类型

1502

Update

CA score added as part of scoring system release. LOE assigned following curator review.

1501

Update

Added CPIC function and modified text. This changes because CPIC assigned this normal function.

1500

Update

Attached CPIC guideline and removed override.

1499

Create